Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, the authors compared topical diphencyprone and tretinoin gel for treating alopecia totalis and universalis, but the abstract does not report any definitive clinical results.

Oral dexamethasone may help regrow hair in adults with alopecia totalis and universalis.

This report describes two patients with alopecia universalis, onychodystrophy, and vitiligo, and found no underlying systemic or etiological causes through extensive investigations.

This study reported two cases of alopecia universalis triggered by PEG-interferon and ribavirin therapy for chronic hepatitis C, with hair regrowth observed after therapy completion or withdrawal.

In this study, treating refractory alopecia universalis with low-dose cyclosporine A and prednisolone improved symptoms, with no recurring alopecia six months post-treatment and enhancements in immunologic function.

This report describes a case where treatment with the JAK inhibitor ruxolitinib significantly improved beard growth in a patient with severe alopecia areata, emphasizing its potential benefits for populations where beard hair holds cultural significance.

This case study reports that abrocitinib therapy led to clinical remission of alopecia universalis in a patient with a history of drug-induced DRESS, suggesting its potential as a treatment option.

This study reports a case where a biologic medication used for atopic dermatitis unexpectedly also treated concurrent alopecia areata.

In this retrospective study, anti-tuberculous agents, likely rifampicin, were effective adjunctive therapies for a chalazion, coinciding with spontaneous drainage in a patient with rosacea.

Sulfasalazine can cause severe allergic reactions leading to long-term autoimmune issues like hair loss and skin discoloration.

This study identified several significant genetic variants associated with alopecia universalis, including a novel association with HLA-DRB5, which may play a hidden role in the disease.

This case report describes a patient with psoriasis and alopecia universalis where psoriasis plaques supported hair growth, suggesting cytokine interaction may influence competing immune responses.

This article reviews the differences in inflammatory processes between alopecia universalis and atopic dermatitis, focusing on type 1 and type 2 immune responses, but it reports no new results.

This review examines the outcomes of treating Brazilian patients with alopecia universalis using tofacitinib and highlights the need for randomized controlled trials to determine optimal dosing and duration.

This case study reports that a 23-year-old woman with alopecia universalis experienced complete hair regrowth after six months of treatment with tofacitinib, a JAK-3 inhibitor.

This report describes a case of universal alopecia in a patient with rheumatoid arthritis while using adalimumab and leflunomide, suggesting a potential link between these drugs and alopecia areata.

In this report, a 19-year-old Japanese man experienced severe and prolonged urticarial reactions following treatment with diphenylcyclopropenone for alopecia universalis, emphasizing the need for caution with potent sensitizers.

This case report describes alopecia universalis-like hair loss occurring in two patients with cutaneous T cell lymphoma, providing clinical, dermoscopic, and pathologic features to help differentiate it from alopecia areata universalis.

Upadacitinib effectively treated severe hair loss in a child.

Tofacitinib, an arthritis drug, helped hair growth in alopecia universalis but long-term safety needs more research.

Ruxolitinib treatment led to unexpected hair regrowth in a patient with alopecia universalis.

In this study, 308-nm excimer light therapy showed significant effects in some patients with treatment-resistant alopecia universalis, suggesting it as a potential alternative therapy.

This case report observed hair regrowth following the treatment of alopecia universalis and atopic dermatitis with tofacitinib, a JAK inhibitor.

In this study, oral tofacitinib showed higher efficacy and tolerability in treating refractory alopecia totalis and universalis compared to traditional treatments, achieving a 50% improvement in severity scores for 44.4% of patients over six months, with fewer adverse effects.

In this case report, a 23-year-old man with Crohn's disease experienced near-complete resolution of alopecia universalis after 7 months of upadacitinib treatment, suggesting potential benefits for treating concurrent alopecia areata and Crohn's disease.

This case report describes a 14-year-old girl with alopecia universalis and mild atopic dermatitis who achieved complete hair regrowth and eczema resolution after three months of treatment with the JAK1 inhibitor upadacitinib.

This article discusses alopecia areata, highlighting its autoimmune nature and the lack of FDA-approved treatments, without providing new research findings.

This study reports a rare case of a 40-year-old woman with multiple calcified trichilemmal cysts, associated with alopecia universalis and suggesting a potential genetic link.

This case study reports the first instance of irreversible alopecia universalis occurring during pegylated interferon-ribavirin therapy in a man with hepatitis C infection, without evidence of immunological or thyroid disorders.

This case report describes a middle-aged man with alopecia universalis and ulcerative colitis, where hair regrowth occurred following treatment with azathioprine and mesalamine.